Josamycin, a new macrolide antibiotic, was compared with ampicillin, erythromycin, and clindamycin in vitro against 25 isolates each of pneumococci, enterococci, Staphylococcus aureus, S. epidermidis, and nonenterococcal hemolytic streptococci and against 25 anaerobes including 10 Bacteroides fragilis. Minimal inhibitory concentration and minimal bactericidal concentration data were obtained for the aerobic organisms, using serial twofold tube dilutions in Mueller-Hinton broth. Minimal inhibitory concentrations were determined for the anaerobes by the agar dilution technique. Josamycin was comparable to erythromycin and clindamycin in activity against the pneumococci, streptococci, and staphylococci and was more active than clindamycin against enterococci. It was somewhat less active than ampicillin against enterococci and S. epidermidis and showed its greatest in vitro activity against anaerobes, being comparable to clindamycin.
Josamycin is a new macrolide antibiotic produced by Streptomyces narbonensis var. josamyceticus. It has been reported to have antibacterial activity similar to that of other macrolides, such as erythromycin, and similar to that of cindamycin. Its antibacterial spectrum includes many of the aerobic gram-positive cocci and mycoplasma, and it has some activity against anaerobic organisms (6) .
Josamycin appears to be well tolerated and without serious toxicity. Achievable concentrations in serum after oral administration ofjosamycin compare favorably with those obtained with erythromycin stearate; the average peak concentration is 1 to 2 ug/ml after a single oral dose of 600 mg (2, 4, 6) .
Because of the potentially serious side effects and toxicities of the two currently available antibiotics that have good activity against anaerobes, namely, chloramphenicol and clindamycin, any new antibiotic that shows significant activity against common anaerobic pathogens may be worth investigation. Thus we studied the efficacy of josamycin in vitro against several different groups of organisms isolated from clinical specimens, including aerobic and anaerobic strains, and compared it with erythromycin, clindamycin, and ampicillin.
MATERIALS AND METHODS Bacterial isolates. We tested 25 isolates each of enterococci, pneumococci, Staphylococcus aureus, S. epidermidis, and nonenterococcal hemolytic streptococci, which included 11 alpha-hemolytic and 14 group A beta-hemolytic streptococci. Twenty-five anaerobic isolates were also tested ( Table 1 ). All aerobic and anaerobic organisms were isolated from human clinical specimens, and all were considered to be clinically significant pathogens. Enterococci were identified by characteristic appearance on PSE plates and by ability to grow in 6.5% saline and SF Media (Difco). Pneumococci were differentiated from other alpha-hemolytic streptococci by optochin disk susceptibility. Group A streptococci were identified by low-concentration bacitracin disk susceptibility. S. aureus isolates were differentiated from S. epidermidis by their ability to ferment mannitol anaerobically, by coagulase production, and by acid production on mannitol salt agar aerobically (1). Anaerobes were identified by the Virginia Polytechnic Institute method (7). Susceptibility testing. Antibiotic susceptibility of the aerobic organisms was determined by serial twofold tube dilutions utilizing Mueller-Hinton broth. The enterococcal and staphylococcal inocula were prepared by using a 1:1,000 dilution of an overnight broth culture, with inoculum preparations averaging 2.3 x 105 organisms/ml. The pneumococcal and hemolytic streptococcal inocula were prepared from overnight cultures in Mueller-Hinton broth and were diluted using a spectrophotometer to give a concentration of 105 organisms/ml. A 0. 1-ml amount of inoculum was pipetted into each tube containing 1 ml of a serial twofold dilution of the antibiotic. The tubes were incubated overnight, and the lowest concentration showing no turbidity was considered the minimal inhibitory concentration (MIC). An aliquot of 0.03 ml was taken by a calibrated loop from each of the clear tubes, streaked onto blood agar plates, and incubated overnight. The lowest concentration representing 95% kill or showing less than five colonies on subculture was considered the minimal bactericidal concentration (MBC).
Susceptibility testing of the anaerobic bacteria was performed using the agar dilution technique (7, 8) . The inocula were prepared in modified thioglycollate medium enriched with 5 lAg of hemin per ml, one ug of NaHCO3 per ml, and 0.5 ,ug of menadione per ml. The inocula were incubated for 6 h when fast-growing and overnight when slow-growing organisms were under test and then diluted in Brucella broth to a turbidity of a no. 1 MacFarland standard. The inoculum was applied with a modified Steers replicator to plates containing serial twofold dilutions of the antibiotic prepared with 5% laked sheep blood and 0.5 ,ug of menadione per ml. The plates were incubated at 37 C in GasPak jars, and the MICs were read at 48 h. Pneumocci. Figure 1 shows the MIC data for 25 isolates of pneumococci. Josamycin showed good activity against 100% of the isolates; they were inhibited by 0.2 ,g or less per ml. Clindamycin was the most active of the antibiotics; 100% were inhibited by 0.025 gg/ml. Erythromycin and ampicillin showed very similar results, with 100% of the isolates inhibited by 0.39 ,ug of ampicillin per ml and 0.78 ,g of erythromycin per ml. The MBCs were determined (Tables 2 through 5), and josamycin at 0.39 ,ug/ml showed bactericidal activity against 100% of the isolates. Clindamycin at 0.05 ug/ml was bactericidal for 100% of the isolates, and ampicillin and erythromycin were bactericidal for 100% of the isolates at concentrations of 0.78 and 1.56 jig/ml, respectively.
RESULTS
Hemolytic streptococci. Eleven isolates of alpha-hemolytic streptococci and 14 isolates of group A beta-hemolytic streptococci were tested. Figure 2 shows the combined cumulative percentage of the organisms inhibited by each of the antibiotics. Josamycin showed good activity against the streptococci, with 100% inhibited by 0.39 ,g/ml. Clindamycin and erythromycin were most active, with 100% of the isolates inhibited by 0.05 ,g/ml. Ampicillin was intermediate in activity, with 100% of strains susceptible to 0.2 ,ug/ml. Josamycin and ampicillin in a concentration of 0.78 ,ug/ml were bactericidal for 100% of the isolates. Clindamycin and erythromycin at 0.2 ,g/ml showed bactericidal activity for 100% of the isolates.
Enterococci. With clindamycin, erythromy- cin, and josamycin, there were significant numbers of resistant organisms at achievable blood level concentrations (Fig. 3) . At 1.56 ,g/ml, 80% were inhibited by erythromycin and 76% were inhibited by josamycin. Clindamycin was least active, with 8% inhibited by 6.25 ,g/ml. All isolates were inhibited by ampicillin at 3.12
Mg/ml. At 1.56 ,ug/ml, erythromycin was bactericidal for only 4% and josamycin was bactericidal for 20% of strains. Clindamycin at that concentration was bactericidal for none of the isolates. Ampicillin was bactericidal for 52% at a concentration of 3.12 ug/ml. Staphylococci. Figure 4 shows the data obtained with 25 isolates of S. epidermidis. Clindamycin was the most active, and 0.1 ,g/ml inhibited 88% of strains. At 1.56 ug/ml, 88% of the isolates were inhibited by josamycin and 100% were inhibited by ampicillin. Erythromycin inhibited 88% of the isolates at 0.39 ,ug/ml. Twelve percent of these isolates were not inhibited by greater than 100 ug of clindamycin, erythromycin, or josamycin per ml. At 1.56 ,ug/ ml, josamycin was bactericidal for 16%, clindamycin for 72%, erythromycin for 32%, and ampicillin for 84% of strains.
Clindamycin was more active in lower concentrations than erythromycin, josamycin, or ampicillin against S. aureus (Fig. 5) . Ninetysix percent of strains were inhibited by clinda- mycin at 0.2 ,ug/ml, whereas 4% were resistant to greater than 100 ,ug/ml. Erythromycin inhibited 88% of the isolates at 0.39 ug/ml. Josamycin inhibited 76% at 1.56 ,ug/ml, whereas ampicillin inhibited 92% at 1.56 jig/ml. At a concentration of 1.56 ,g/ml, clindamycin was bactericidal for 68%, ampicillin for 72%, erythromycin for 32%, and josamycin for 8%.
Anaerobes. Table 1 shows the identification of the anaerobic strains tested. A heterogeneous group was used, but 10 of the 25 isolates were Bacteroides fragilis. Figure 6 and Tables  2 through 5 summarize the antibiotic concentrations required for inhibition of all the anaerobic isolates. Josamycin and clindamycin were the most active, with 96% of the isolates inhibited by 1.56 jig of either antibiotic per ml.
The one organism resistant to more than 1.56 ,ug of clindamycin per ml was a strain of Clos- It is known that the in vitro activity of macrolides in general and erythromycin specifically decreases with lower pH and increasing concentrations of C02 (5) . The Japanese data suggest that this occurs with josamycin as well (6) . Since our anaerobic testing was done under increased C02 tension, it is possible that the anaerobic isolates would show greater susceptibility to erythromycin and josamycin under physiological conditions than our data would indicate. Nevertheless, josamycin showed its greatest activity against anaerobic bacteria, being quite similar to clindamycin in vitro against clinically significant anaerobes, including B. fragilis. It showed significantly greater activity than either erythromycin or ampicillin against common anaerobic pathogens.
